221 related articles for article (PubMed ID: 28486193)
1. Wogonin mitigates nonalcoholic fatty liver disease via enhancing PPARα/AdipoR2, in vivo and in vitro.
Chen J; Liu J; Wang Y; Hu X; Zhou F; Hu Y; Yuan Y; Xu Y
Biomed Pharmacother; 2017 Jul; 91():621-631. PubMed ID: 28486193
[TBL] [Abstract][Full Text] [Related]
2. Alpinetin improved high fat diet-induced non-alcoholic fatty liver disease (NAFLD) through improving oxidative stress, inflammatory response and lipid metabolism.
Zhou Y; Ding YL; Zhang JL; Zhang P; Wang JQ; Li ZH
Biomed Pharmacother; 2018 Jan; 97():1397-1408. PubMed ID: 29156529
[TBL] [Abstract][Full Text] [Related]
3. Sesamin ameliorates hepatic steatosis and inflammation in rats on a high-fat diet via LXRα and PPARα.
Zhang R; Yu Y; Hu S; Zhang J; Yang H; Han B; Cheng Y; Luo X
Nutr Res; 2016 Sep; 36(9):1022-1030. PubMed ID: 27632923
[TBL] [Abstract][Full Text] [Related]
4. Wogonin ameliorates hyperglycemia and dyslipidemia via PPARα activation in db/db mice.
Bak EJ; Kim J; Choi YH; Kim JH; Lee DE; Woo GH; Cha JH; Yoo YJ
Clin Nutr; 2014 Feb; 33(1):156-63. PubMed ID: 23623334
[TBL] [Abstract][Full Text] [Related]
5. Danthron ameliorates obesity and MAFLD through activating the interplay between PPARα/RXRα heterodimer and adiponectin receptor 2.
Ma C; Wang Z; Xia R; Wei L; Zhang C; Zhang J; Zhao L; Wu H; Kang L; Yang S
Biomed Pharmacother; 2021 May; 137():111344. PubMed ID: 33581653
[TBL] [Abstract][Full Text] [Related]
6. Hepatoprotective Effect of Loquat Leaf Flavonoids in PM
Jian T; Ding X; Wu Y; Ren B; Li W; Lv H; Chen J
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30275422
[TBL] [Abstract][Full Text] [Related]
7. Li-Gan-Shi-Liu-Ba-Wei-San improves non-alcoholic fatty liver disease through enhancing lipid oxidation and alleviating oxidation stress.
Jiang Y; Chen L; Wang H; Narisi B; Chen B
J Ethnopharmacol; 2015 Dec; 176():499-507. PubMed ID: 26571089
[TBL] [Abstract][Full Text] [Related]
8. Adiponectin homolog novel osmotin protects obesity/diabetes-induced NAFLD by upregulating AdipoRs/PPARα signaling in ob/ob and db/db transgenic mouse models.
Ahmad A; Ali T; Kim MW; Khan A; Jo MH; Rehman SU; Khan MS; Abid NB; Khan M; Ullah R; Jo MG; Kim MO
Metabolism; 2019 Jan; 90():31-43. PubMed ID: 30473057
[TBL] [Abstract][Full Text] [Related]
9. The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease.
Gao H; Zeng Z; Zhang H; Zhou X; Guan L; Deng W; Xu L
Biol Pharm Bull; 2015; 38(5):694-702. PubMed ID: 25947915
[TBL] [Abstract][Full Text] [Related]
10. Protective effect and mechanism of Qiwei Tiexie capsule on 3T3-L1 adipocytes cells and rats with nonalcoholic fatty liver disease by regulating LXRα, PPARγ, and NF-κB-iNOS-NO signaling pathways.
Suolang PC; Liu BQ; Chen J; De J; Nima ZB; Dunzhu CR
J Ethnopharmacol; 2019 May; 236():316-325. PubMed ID: 30851372
[TBL] [Abstract][Full Text] [Related]
11. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
[TBL] [Abstract][Full Text] [Related]
12. Hepatic AdipoR2 signaling plays a protective role against progression of nonalcoholic steatohepatitis in mice.
Tomita K; Oike Y; Teratani T; Taguchi T; Noguchi M; Suzuki T; Mizutani A; Yokoyama H; Irie R; Sumimoto H; Takayanagi A; Miyashita K; Akao M; Tabata M; Tamiya G; Ohkura T; Hibi T
Hepatology; 2008 Aug; 48(2):458-73. PubMed ID: 18666257
[TBL] [Abstract][Full Text] [Related]
13. Low molecular weight fucoidan attenuates liver injury via SIRT1/AMPK/PGC1α axis in db/db mice.
Zheng Y; Liu T; Wang Z; Xu Y; Zhang Q; Luo D
Int J Biol Macromol; 2018 Jun; 112():929-936. PubMed ID: 29447962
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin aggravates hepatic oxidative stress, inflammation and fibrosis in a non‑alcoholic fatty liver disease mouse model.
Lu Y; Lin Y; Huang X; Wu S; Wei J; Yang C
Int J Mol Med; 2019 Jun; 43(6):2398-2408. PubMed ID: 30942432
[TBL] [Abstract][Full Text] [Related]
15. Paeoniflorin Protects against Nonalcoholic Fatty Liver Disease Induced by a High-Fat Diet in Mice.
Zhang L; Yang B; Yu B
Biol Pharm Bull; 2015; 38(7):1005-11. PubMed ID: 25972092
[TBL] [Abstract][Full Text] [Related]
16. Sodium Butyrate Ameliorates High-Fat-Diet-Induced Non-alcoholic Fatty Liver Disease through Peroxisome Proliferator-Activated Receptor α-Mediated Activation of β Oxidation and Suppression of Inflammation.
Sun B; Jia Y; Hong J; Sun Q; Gao S; Hu Y; Zhao N; Zhao R
J Agric Food Chem; 2018 Jul; 66(29):7633-7642. PubMed ID: 29961332
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of microRNA-375 regulates adipokines and inhibits inflammatory cytokines by targeting AdipoR2 in non-alcoholic fatty liver disease.
Lei L; Zhou C; Yang X; Li L
Clin Exp Pharmacol Physiol; 2018 Aug; 45(8):819-831. PubMed ID: 29569260
[TBL] [Abstract][Full Text] [Related]
18. Triterpenoid-rich fraction from Ilex hainanensis Merr. attenuates non-alcoholic fatty liver disease induced by high fat diet in rats.
Cui WX; Yang J; Chen XQ; Mao Q; Wei XL; Wen XD; Wang Q
Am J Chin Med; 2013; 41(3):487-502. PubMed ID: 23711137
[TBL] [Abstract][Full Text] [Related]
19. Thymoquinone alleviates nonalcoholic fatty liver disease in rats via suppression of oxidative stress, inflammation, apoptosis.
Awad AS; Abd Al Haleem EN; El-Bakly WM; Sherief MA
Naunyn Schmiedebergs Arch Pharmacol; 2016 Apr; 389(4):381-91. PubMed ID: 26753695
[TBL] [Abstract][Full Text] [Related]
20. AdipoR1/AdipoR2 dual agonist recovers nonalcoholic steatohepatitis and related fibrosis via endoplasmic reticulum-mitochondria axis.
Xu H; Zhao Q; Song N; Yan Z; Lin R; Wu S; Jiang L; Hong S; Xie J; Zhou H; Wang R; Jiang X
Nat Commun; 2020 Nov; 11(1):5807. PubMed ID: 33199780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
